Abstract
Objective: To analyze hepatic encephalopathy (HE) in the emergency department. Bibliographic review: HE is defined as the symptomatic loss of normal brain function caused by liver failure and/or portosystemic shunt, manifesting as a wide spectrum of neurological or psychiatric abnormalities, ranging from subclinical changes to coma. HE can be caused by low levels of oxygen in the body, use of medications such as benzodiazepines, antidepressants, and antipsychotics, as well as decreased bowel movements, gastrointestinal bleeding, excessive alcohol consumption, sepsis, and kidney irregularities. Gastrointestinal bleeding is the most frequent trigger associated with HE, probably because this condition is more common in patients with cirrhosis than in the general population. Final considerations: HE is one of the main and most serious complications of liver cirrhosis in the emergency department. In this context, prompt recognition of this condition is essential. Its treatment is primarily through supportive care and stabilization; the identification of precipitating factors; adequate nutritional support with a protein intake of 1.2 to 1.5 g/kg/day, in addition to medications such as lactulose, lactilol and rifaximin.
References
BELLAFANTE D, et al. Old and New Precipitants in Hepatic Encephalopathy: A New Look at a Field in Continuous Evolution. J Clin Med, 2023; 12(3): 1187.
CORONEL-CASTILLO CE, et al. Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathy. Rev Gastroenterol Mex (Engl Ed), 2020; 85(1): 56-68.
GREEN EW e MITRA A. Diagnosis and management of hepatic encephalopathy: A summary for patients. Clin Liver Dis (Hoboken), 2022; 20(3): 90-92.
HADJIHAMBI A, et al. Hepatic encephalopathy: a critical current review. Hepatol Int, 2018; 12(1): 135-147.
HASAN LZ e WU GY. Novel Agents in the Management of Hepatic Encephalopathy: A Review. J Clin Transl Hepatol, 2021; 9(5): 749-759.
HAUSSINGER D, et al. Pathomechanisms in hepatic encephalopathy. Biol Chem, 2021; 402(9): 1087-1102.
HOILAT GJ, et al. Evidence-based approach to management of hepatic encephalopathy in adults. World J Hepatol, 2022; 14(4): 670-681.
HOILAT GJ, et al. Polyethylene glycol versus lactulose in the treatment of hepatic encephalopathy: a systematic review and meta-analysis. BMJ Open Gastroenterol, 2021; 8(1): e000648.
LOUISSAINT J, et al. Changing Epidemiology of Cirrhosis and Hepatic Encephalopathy. Clin Gastroenterol Hepatol, 2022; 20(8): 1-8.
MA YJ, et al. Proton pump inhibitor use increases hepatic encephalopathy risk: A systematic review and meta-analysis. World J Gastroenterol, 2019; 25(21): 2675-2682.
RAHIMI RS, et al. Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes. Am J Med, 2021; 134(11): 1330-1338.
RIDOLA L e RIGGIO O. Hepatic Encephalopathy in the 21st Century: Still an Emerging Topic. J Clin Med, 2021; 10(2): 298.
SHARMA K, et al. Hepatic Encephalopathy and Treatment Modalities: A Review Article. Cureus, 2022; 14(8): e28016.
SHAW J, et al. Inadequate practices for hepatic encephalopathy management in the inpatient setting. J Hosp Med, 2022; 17(1): 8-16.
TAPPER EB, et al. Review article: current and emerging therapies for the management of cirrhosis and its complications. Aliment Pharmacol Ther, 2022; 55(9): 1099-1115.
VELARDE-RUIZ JAV, et al. Evaluation and management of emergencies in the patient with cirrhosis. Rev Gastroenterol Mex (Engl Ed), 2022; 87(2): 198-215.
VIDAL-CEVALLOS P, et al. Current approaches to hepatic encephalopathy. Ann 100757. Hepatol, 2022; 27(6).
YU H, et al. Prognostic value of hepatic encephalopathy for survival of patients with liver failure: A systematic review and meta-analysis. Ann Hepatol, 2019; 18(4): 607-612.
WEI F, et al. Impact of Optimizing the Emergency Care Process on the Emergency Effect and Prognosis of Patients with Hepatic Encephalopathy. Emerg Med Int, 2022; 2022: 4446215.
WEISSENBORN K. Hepatic Encephalopathy: Definition, Clinical Grading and Diagnostic Principles. Drugs, 2019; 79(1): 5-9.
